Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The analysis of a cohort of consecutive non-selected patients from the Strasbourg University Hospital, and therefore representative of the real life, will allow better identifying the risk factors for these infections (by comparison with a cohort of patient with similar conditions of immunosuppression and no infection) and improving the diagnosis and therapeutic management.
The primary objective is to identify prognosis factors affecting survival in patients with opportunistic infections
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Opportunistic infection | Immunocompromised or frail patients with an opportunistic infection | ||
| Control group | Immunocompromised or frail patients with no opportunistic infection |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Short- and long-term survival, overall and in specific subgroups of patients | Long-term time point : 1st may 2019 | |
| Short- and long-term survival, overall and in specific subgroups of patients | Short term : 1 month | |
| Short- and long-term survival, overall and in specific subgroups of patients | Short term : 3 months | |
| Short- and long-term survival, overall and in specific subgroups of patients | Short term : 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Risk factors predisposing to opportunistic infections - age - gender - Type of work - Location - Tobacco use | first day of opportunistic infection | |
| Prognosis factors in patients with opportunistic infection affecting the response to antimicrobial therapy (using response criteria defined by EORTC/MSG) |
Not provided
Inclusion criteria:
Exclusion criteria:
- Opposition of the patient to use his personal data
Not provided
Not provided
Not provided
Not provided
Not provided
Patients hospitalized in any department of the University Hospital of Strasbourg since 1997 Opportunistic infectious disease occurrence in immunocompromised or frail patients.
In case of epidemiological study, patients from a control group with the same characteristics but without infection can be included.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Raoul HERBRECHT, MD | Contact | 03 88 12 83 79 | 0033 | raoul.herbrecht@chru-strasbourg.fr |
| Name | Affiliation | Role |
|---|---|---|
| Raoul HERBRECHT, MD | University Hospital, Strasbourg, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital, Strasbourg, france | Recruiting | Strasbourg | 67091 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D016638 | Critical Illness |
| ID | Term |
|---|---|
| D006425 | Hemic and Lymphatic Diseases |
| D007154 | Immune System Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
| first day of opportunistic infection |
| Identification of baseline prognosis factors affecting the 3 months survival | first day of opportunistic infection |
| Identification of baseline prognosis factors affecting the 6 months survival | first day of opportunistic infection |
| Incidence of specific opportunistic infections in different host groups | evolution of a 20-year-period |
| Description of imaging patterns opportunistic infections: analysis of chest CT-scan and cerebral CT-scan and MRI by radiologists | at first day of infection and up to 12 weeks |
| Assessment of performance of Aspergillus galactomannan detection test in serum | at onset and up to 1 week |
| Assessment of performance of Aspergillus galactomannan detection test in bronchoalveolar lavage | at onset and up to 1 week |
| Response rate | at 1, 3 and 6 months |
| D013568 | Pathological Conditions, Signs and Symptoms |